B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update for JY231 injection in relapsed or refractory B-cell lymphomas and leukemias, currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
Mayo Clinic is conducting a Phase 1 clinical trial evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies…
-
CLINICAL_TRIALS research · 2025-06-23Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 ) [Phase 1]
A Phase 1 clinical study evaluating CT1190B (CT1190B-CG1101) in relapsed/refractory B-cell non-Hodgkin lymphoma; the trial is currently not …
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
This clinical trial update indicates that JY231 injection is being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B…
-
CLINICAL_TRIALS research · 2025-06-09Clinical Trial Update: A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas [Phase 1]
This clinical trial update reports that ATG-031 is being studied in a Phase 1 trial for patients with advanced solid tumors or B-cell non-Ho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL [NA]
Recruitment is ongoing for JCXH-213 to evaluate its safety, tolerability, and efficacy in patients with recurrent or refractory B-cell non-H…
-
CLINICAL_TRIALS research · 2025-05-25Clinical Trial Update: TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating TRAC and SPPL3 gene-knockout allogeneic CD19-targeting CAR-T cells for relapsed/refractory B-cell non-…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance [Phase 1, Phase 2]
A Phase 1/2 study of blinatumomab in patients with Pre-B cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma as remission main…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial update evaluating the safety and efficacy of DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malign…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase Ib trial evaluating Rocbrutinib in combination with R-CHOP for newly diagnosed B-cell Non-Hodgkin Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies [Phase 1]
A Phase 1 clinical trial of RS001 in relapsed/refractory B-cell malignancies, including B-cell Non-Hodgkin's Lymphoma and Acute Lymphoblasti…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [Phase 1]
A Phase 1 trial evaluating a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy (ANTLER) for relapsed/refractory B-cell non-Hodgkin lymph…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma [NA]
Clinical trial update for JY231 injection for relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL [Phase 1]
Phase 1 clinical trial evaluating cord blood-derived CAR-NK cells targeting CD19 for refractory or relapsed B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update for CT1190B in relapsed/refractory B-cell non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL [Phase 2]
A Phase 2 clinical trial is evaluating immunobridging/maintenance therapy versus non-bridging therapy in CAR-T treatment for low-risk relaps…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating subcutaneous epcoritamab as monotherapy or with standard-of-care therapies in adults in China with B-c…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CT1190B for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2024-12-10Clinical Trial Update: A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma [Phase 1]
This update reports on a Phase 1 clinical trial of JMT601 in relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, currently rec…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research [EARLY_Phase 1]
This clinical trial from Zhejiang University is evaluating the safety and potential efficacy of Meta10-19 metabolically armed CD19 CAR-T cel…
-
CLINICAL_TRIALS research · 2024-11-21Clinical Trial Update: To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) [Phase 2]
A Phase 2 trial is evaluating the safety and efficacy of autologous CD19 CAR-T cells for relapsed/refractory B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
Clinical trial update for JY231 Injection studying its use in relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia…
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial evaluating a CD19/CD20 dual-targeted cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma is currently recrui…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT [Phase 2]
Phase 2 trial update on ARTA-based chemo-free bridging and maintenance therapy accompanying CAR-T treatment for high-risk relapsed/refractor…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma is currently recruiting.